


SOLIRIS / ULTOMIRIS REFERRAL FORM		Y Medical Associates Fax Referral To: 855-838-0623 Phone: 800-447-7558			
Date: _____					
Patient Information			Prescriber Information		
Patient Name: _____ Address: _____ City, State, Zip: _____ Home Phone: _____ Cell Phone: _____ DOB: _____ Gender: <input type="checkbox"/> M <input type="checkbox"/> F			Prescriber Name: _____ Address: _____ City, State, Zip: _____ Phone: _____ Fax: _____ DEA: _____ NPI #: _____ Contact Person: _____		
INSURANCE INFORMATION (Please attach the front and back of insurance and prescription drug cards)					
Primary Insurance: _____		ID#: _____		Group: _____	
Secondary Insurance: _____		ID#: _____		Group: _____	
Prescription Card: _____		BIN#: _____ PCN#: _____		Group: _____	
DIAGNOSIS & CLINICAL ASSESSMENT (Fill in below or attach lab work)					
<input type="checkbox"/> New to Therapy <input type="checkbox"/> Currently on Therapy <input type="checkbox"/> Date of Last IVIG Infusion: _____ <input type="checkbox"/> IVIG Dosing Regimen: _____					
Diagnosis: <input type="checkbox"/> G70.00 Myasthenia Gravis without (acute) exacerbation <input type="checkbox"/> G70.01 Myasthenia Gravis with (acute) exacerbation <input type="checkbox"/> in crisis					
<input type="checkbox"/> D59.3 atypical Hemolytic Uremic Syndrome (aHUS) <input type="checkbox"/> D59.5 PNH <input type="checkbox"/> G36.0 Neuromyelitis Optica Date of Diagnosis: _____					
Weight: _____ Height: _____ Date: _____ Allergies: _____ Date of MenACWY: _____ Date of MenB: _____					
Previously on PLEX treatment <input type="checkbox"/> Yes <input type="checkbox"/> No Date of last treatment: _____ Is patient AchR antibody positive? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the Patient Anti-Aquaporin-4 (AQP4) antibody positive? <input type="checkbox"/> Yes <input type="checkbox"/> No Notes/Comments: _____					
Soliris (eculizumab)			Ultomiris (ravulizumab)		
Strength		Directions		Strength	
Injection: 300mg / 30mL (10mg/mL) in a single-dose vial		<input type="checkbox"/> For treatment of Myasthenia Gravis: <input type="checkbox"/> 900mg weekly for the first 4 weeks, followed by <input type="checkbox"/> 1200mg for the fifth dose 1 week later, then <input type="checkbox"/> 1200mg every 2 weeks thereafter. <input type="checkbox"/> For treatment of aHUS – 18 years or older: <input type="checkbox"/> 900mg weekly for the first 4 weeks, followed by <input type="checkbox"/> 1200mg for the fifth dose 1 week later, then <input type="checkbox"/> 1200mg every 2 weeks thereafter. <input type="checkbox"/> For treatment of NMOSD: <input type="checkbox"/> 900mg weekly for the first 4 weeks, followed by <input type="checkbox"/> 1200mg for the fifth dose 1 week later, then <input type="checkbox"/> 1200mg every 2 weeks thereafter. <input type="checkbox"/> For treatment of PNH – 18 years or older: <input type="checkbox"/> 600mg weekly for the first 4 weeks, followed by <input type="checkbox"/> 900mg for the fifth dose 1 week later, then <input type="checkbox"/> 900mg every 2 weeks thereafter. Orders and Medications Other: _____		Injection: 300mg/30mL (10mg/mL) in a single dose vial <input type="checkbox"/> 300mg/3 mL (100mg/mL) in a single dose vial <input type="checkbox"/> 1,100mg/11mL (100mg/mL) in a single dose vial * Do not mix ULTOMIRIS 100 mg/mL (3mL and 11mL vials) and 10mg/mL (30mL vial) concentrations together. **When switching therapy: Ultomiris loading dose should be given at the time of next scheduled Soliris dose.	
				<input type="checkbox"/> For treatment of Myasthenia Gravis - weight based at time of treatment (patient must be at least 40kg): <input type="checkbox"/> _____mg as a single dose, followed by <input type="checkbox"/> _____mg once every 8 weeks later starting 2 weeks after the loading dose. <input type="checkbox"/> For treatment of aHUS – weight based at time of treatment: <input type="checkbox"/> _____mg as a single dose, followed by <input type="checkbox"/> _____mg once every _____ (4 or 8) weeks later starting 2 weeks after the loading dose. <input type="checkbox"/> For treatment of PNH – weight based at time of treatment: <input type="checkbox"/> _____mg as a single dose, followed by <input type="checkbox"/> _____mg once every _____ (4 or 8) weeks later starting 2 weeks after the loading dose. Other: _____	
Anaphylaxis Orders					
Diphenhydramine Administer 25 mg slow IV/IM may repeat x1 Dispense: 1 x 50 mg vial					
Epinephrine Autoinjector <input type="checkbox"/> Administer 0.15mg (1:2000) IM (< 30 Kg) Dispense: 1 package (2 pens) <input type="checkbox"/> Administer 0.3mg (1:1000) IM (≥ 30 Kg)					
Sodium Chloride 0.9% Use to maintain IV line, prevent or treat hypotension in case of anaphylaxis Dispense: QS					
IV Access Flush Order:					
NaCl 0.9% 5-10mL IV before and after infusion Heparin 10 Units/mL 5mL after infusion for PICC/Midline Heparin 10 Units/mL 3mL after infusion for PIV Heparin 100 Units/mL 5mL IV after infusion for PORT All infusion supplies necessary to administer the medication					
Quantity		Refills			
Other/Notes: _____					
Prescriber Signature: _____ DAW (Dispense as Written) <input type="checkbox"/> Y <input type="checkbox"/> N Date: _____					